ZyVersa Therapeutics (ZVSA) Projected to Post Quarterly Earnings on Monday

ZyVersa Therapeutics (NASDAQ:ZVSA) is expected to issue its quarterly earnings data before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($6.30) per share for the quarter.

ZyVersa Therapeutics Stock Up 6.3 %

Shares of ZVSA opened at $0.75 on Friday. The stock’s fifty day simple moving average is $1.17 and its 200-day simple moving average is $1.52. ZyVersa Therapeutics has a 12-month low of $0.70 and a 12-month high of $8.40.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.